|
FDA Approves Reformulated Ranitidine - Nitrosamine Impurities - NDMA
|
|
3
|
455
|
November 27, 2025
|
|
Addendum to ICH M7 on Risk Assessment and Control of N-Nitrosamine Impurities
|
|
8
|
2232
|
July 3, 2025
|
|
🇲🇽 Free Lhasa México Symposia: Shaping the Future of Pharma & Regulation 🇲🇽
|
|
0
|
132
|
May 13, 2025
|
|
Industrial Case Studies Demonstrating Applicability of ICH M7Control Options 3 and 4 for Nitrosamine Control -Pub
|
|
4
|
762
|
April 22, 2025
|
|
ICH M7 & Nitrosamines Impurities -Updates
|
|
15
|
4997
|
January 20, 2025
|
|
Synthesis and mutagenic risk of avanafil's potential genotoxic impurities -Pub
|
|
0
|
153
|
August 25, 2024
|
|
Classification of potentially mutagenic impurities under the ICH M7 guideline -Event
|
|
0
|
420
|
July 23, 2024
|
|
Leveraging ICH M7 Control Options 3 and 4: Discussion and Clarification Using Industrial Case Studies -Pub
|
|
0
|
624
|
July 23, 2024
|
|
Non-mutagenic, carcinogenic impurities
|
|
3
|
689
|
June 30, 2024
|